1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
BioELife Corp.

BioELife Corp.

LITH
BioELife Corp.US flagOther OTC
0.00
USD
- -
- -
941.00Market Cap
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.06
-0.05
-0.05
-0.06
-0.08
-0.08
-0.06
-0.44
-0.04
-0.09
-0.1
-0.13
-0.18
Free Cash Flow per Basic Share
-0.05
-0.05
-0.04
-0.05
-0.06
-0.04
-0.06
-0.03
-0.02
-0.06
-0.05
-0.03
-0.06
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.02
-0.07
-0.12
-0.19
-0.27
-0.35
-0.41
-0.82
-0.51
-0.52
-0.61
-0.71
-0.57
Tangible Book Value per Share
0.03
-0.02
-0.07
-0.13
-0.16
-0.24
-0.29
-0.33
-0.12
-0.13
-0.03
-0.12
- -
Basic Weighted Avg Shares
1
1
1
1
1
1
1
1
2
2
2
3
3
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.46
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
5
5
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
73.04%
59.62%
360.49%
Free Cash Flow
23.14%
41.58%
-37.16%
Net Income, GAAP
80.45%
153.89%
36.5%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
-0.03
-0.02
-0.02
- -
-0.1
2018
-0.02
0.07
0.01
- -
-0.13
2019
0.03
-0.04
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Michael Terpin
Full Time Employees
1
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
12340 Seal Beach Boulevard Seal Beach CA United States of America 90740
IPO Date
Aug 7, 2009
CIK
0001396054
Website
bioelife.com
Similar Companies
Ayurcann Holdings Corp. (AYUR.CN)
Canopy Growth Corporation (CGC)
Huons Co., Ltd. (243070.KQ)
Bright Green Corporation (BGXX)
Neoleukin Therapeutics, Inc. (NLTX)
JBM (Healthcare) Limited (2161.HK)
Business
BioELife Corp. operates within the cannabinoid sector, concentrating on CBD-based offerings. The company presents a variety of cannabinoid products, encompassing adult gummies, tinctures, including specialized options blended with chirorub, an intensive topical relief rub, as well as premium pre-rolls and flowers. Formerly recognized as US Lithium Corp., the organization adopted the BioELife Corp. designation in March of 2020. The firm was established in 2006 and is headquartered in Seal Beach, California.